EPISODE · Mar 12, 2026 · 24 MIN
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
from WTR Small-Cap Spotlight · host Water Tower Research
Send us Fan MailIn this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa’ clinical pipeline and strategic direction. He outlines the company’s plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the Phase 1 study of Lira‑Cel, Anixa’ CAR‑T therapy for ovarian cancer, observed in a terminally ill patient population. Dr. Kumar also details key protocol enhancements in the ongoing Phase 1 trial, to help steer the program toward potentially groundbreaking curative outcomes. Finally, supported by Anixa’s capital‑efficient business model, Dr. Kumar notes that the expansion of clinical data in 2026 could drive meaningful opportunities for pharma partnerships and further validate the company’s broader immunotherapy strategy.
What this episode covers
Send us Fan Mail In this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa’ clinical pipeline and strategic direction. He outlines the company’s plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he em...
NOW PLAYING
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
No transcript for this episode yet
Similar Episodes
Jun 12, 2025 ·30m
Apr 22, 2025 ·32m
Apr 17, 2025 ·16m
Feb 27, 2025 ·0m
Dec 16, 2024 ·39m